Get the Stockscreener App
14.08
0.72%
0.10
After Hours:
15.40
1.32
+9.38%
Inhibrx Biosciences Inc stock is traded at $14.08, with a volume of 55,132.
It is up +0.72% in the last 24 hours and down -10.89% over the past month.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
See More
Previous Close:
$13.98
Open:
$14.08
24h Volume:
55,132
Relative Volume:
0.60
Market Cap:
$203.82M
Revenue:
$1.80M
Net Income/Loss:
$-241.36M
P/E Ratio:
-3.4765
EPS:
-4.05
Net Cash Flow:
$-197.90M
1W Performance:
+1.81%
1M Performance:
-10.89%
6M Performance:
-59.08%
1Y Performance:
-31.45%
1-Day Range:
$13.87
$14.28
1-Week Range:
$13.27
$14.62
52-Week Range:
$10.80
$39.79
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Name
Inhibrx Biosciences Inc
Sector
Industry
Phone
(858) 795-4220
Address
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| INBX | 14.08 | 203.82M | 1.80M | -241.36M | -197.90M | -4.05 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Mar-16-22 | Initiated | SMBC Nikko | Outperform |
| Sep-21-21 | Initiated | JMP Securities | Mkt Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Evercore ISI | Outperform |
View All
Inhibrx Biosciences Inc Stock (INBX) Latest News
Inhibrx Biosciences director Jon Faiz Kayyem buys $1.52m in stock - Investing.com Australia
Trend Tracker for (INBX) - Stock Traders Daily
The recent drop in prices must have disappointed Inhibrx Biosciences, Inc. (NASDAQ:INBX) institutional investors who own 43% of the shares - Yahoo Finance
institutional investors of Inhibrx Biosciences, Inc. (NASDAQ:INBX) must be disappointed after last week's 15% drop - Simply Wall St
Perceptive Advisors LLC Bolsters Stake in Inhibrx Biosciences Inc - GuruFocus.com
Inhibrx Biosciences Inc (INBX) Quarterly 10-Q Report - Quartzy
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results - PR Newswire
Inhibrx Q3 Loss Narrows to $2.84/Share, Maintains $196M Cash for Clinical Programs | INBX Stock News - StockTitan
Inhibrx Biosciences Inc. (INBX) Quarterly 10-Q Report - Quartzy
Wilson Sonsini Knocks Out Claims Against Inhibrx Biosciences in Trade Secrets Verdict - Law.com
Inhibrx Biosciences’ Trade Secret Case - Global Legal Chronicle
(INBX) Trading Signals - Stock Traders Daily
Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform - Seeking Alpha
Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation - Financial Times
James Sabry on industry-shaping changes in innovation and deal-making - BioCentury
Long Term Trading Analysis for (INBX) - Stock Traders Daily
Inhibrx Biosciences' SWOT analysis: cash-rich biotech stock faces pivotal year - Investing.com Australia
Inhibrx Biosciences' SWOT analysis: cash-rich biotech stock faces pivotal year By Investing.com - Investing.com South Africa
How To Trade (INBX) - Stock Traders Daily
why ImmunityBio Inc [IBRX] is a Good Choice for Investors After New Price Target of $6.38 - The DBT News
INVX underperforms with a -2.86 decrease in share price - US Post News
You might want to take a look at Imunon Inc (IMNN) now - SETE News
Immuneering Corp [IMRX] Shares Fall Approximately -71.25% Over the Year - Knox Daily
ImmunityBio, Inc. (NASDAQ:IBRX) Shares Purchased by Private Advisor Group LLC - Defense World
Incyte (NASDAQ:INCY) Given “Hold” Rating at Truist Financial - Defense World
Inhibrx, Inc. (NASDAQ:INBX) Short Interest Down 6.9% in August - Defense World
InnovAge (NASDAQ:INNV) Trading Up 4.2% - Defense World
William Hoffman Sells 40,000 Shares of Inari Medical, Inc. (NASDAQ:NARI) Stock - Defense World
INmune Bio, Inc. (NASDAQ:INMB) Sees Large Increase in Short Interest - Defense World
INmune Bio stock remains a Buy with positive data correlation in Alzheimer’s study, says Scotiabank - Investing.com
A review of IMNN’s current quarter earnings predictions - US Post News
Its Stock Has Paid Off Big Time For INmune Bio Inc - SETE News
Inhibrx, Inc. (NASDAQ:INBX) Short Interest Update - MarketBeat
IBRX Stock on the Rise: A Promising Investment - The InvestChronicle
Market Watch: Immuneering Corp (IMRX)’s Noteworthy Drop, Closing at 2.78 - The Dwinnex
Truist downgrades Incyte to "hold" on doubts of near-term prospects - XM
Incyte (NASDAQ:INCY) Receives Market Perform Rating from JMP Securities - Defense World
Imunon (NASDAQ:IMNN) Shares Up 5.6% - Defense World
Ratio Review: Analyzing Innovex International Inc. (INVX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
10% Owner Of Impinj Makes $20.00M Buy - Benzinga
Inmune Bio CFO acquires $49k in company stock By Investing.com - Investing.com Canada
Inmune Bio CEO acquires $98k in company stock - Investing.com
Inmune Bio CFO buys $49k in company stock - Investing.com
Inhibrx CEO buys shares worth over $629k - Investing.com India
Inhibrx CEO buys shares worth over $629k By Investing.com - Investing.com Canada
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
How will ImmunityBio Inc’s (IBRX) earnings compare to estimates this quarter? - US Post News
What is IMRX’s price-to-sales ratio telling us about the company’s value? - US Post News
Impinj 10% Owner Trades $20.00M In Company Stock - Benzinga
Take off with ImmunityBio Inc (IBRX): Get ready for trading - SETE News
SEC Form 424B5 filed by INmune Bio Inc. - Quantisnow
Inhibrx Biosciences Inc Stock (INBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
2.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):